

| | | |
|------|----|----|
| 2017 | 11 | 07 |
| 2019 | 02 | 21 |
| 2019 | 05 | 22 |
| 2019 | 05 | 24 |
| 2020 | 03 | 11 |
| 2020 | 12 | 11 |
| 2021 | 08 | 05 |
| 2021 | 09 | 14 |

®

Ustekinumab Injection

Wusinu Dankang Zhusheye

L-

L-

80

MTX

PUVA

A

TNF

45mg/0.5ml/

90mg/1.0ml/

45 mg

4

12

100 kg

100 kg

90 mg

4

12

45 mg

90 mg

28

IV

1

8 90mg

12

90mg

1

| | | ^a | 130 mg |
|-------|-------|--------------|--------|
| 55 kg | | 260 mg | 2 |
| 55 kg | 85 kg | 390 mg | 3 |
| 85 kg | | 520 mg | 4 |

a 6 mg/kg

8

12

1

8

1

8

12

1

16

8

1

16

/

8

1

45mg/0.5ml/

90mg/1.0ml/

"

"

"

"

1.34 0.03
 930 30 0.03
 434 15
 6,709 11,581 1.0
 1.1 0.6
 0.91 0.02 11,581
 199

0.11 100
 929 1 0.23 100
 434 1
 0.43 100 929 4 0.46
 100 433 2
 6,709 11,561 1.0
 1.1 0.6 11,561
 62
 0.54 100
 =0.93 [95%
 0.71 1.20]
 0.49 100 11,545
 56 3:1

1%

466

2.4%

470

2.6%

1

(PRES)

2

PRES

RPLS

PRES

1

PRES

PRES

12.4%

3%

/

—

CT

-

T

T cell enzyme-linked immune-spot assay T-SPOT.TB T
Quanti FERON-TB Gold QFT-G

—————

IL-12/IL-23

BCG

IL-12/IL-23

60

PUVA

[BCG]

15

2

MTX

1-3

15

/

15

18

65

65

65

III
 100
 5% 90%
 6- MTX TNF NSAID
 IL-12 IL-23 CYP450
 10 ng/ml IL-12 / IL-23
 CYP450 CYP1A2 2B6 2C9 2C19 2D6 3A4
 CYP450
 IL-1 IL-6 IL-10 TNF IFN
 IL-12 IL-23 CYP450 CYP450
 CYP450
 MTX
 6 mg/kg

| | | | | | | | | | | |
|-------|-------|-------|-----------|-----|-------|----|---|-------|-------|------|
| <hr/> | | | | | | | | | | |
| | 2 | | | | | | | | 1,996 | |
| 1 | | | | | | | | MTX | PUVA | |
| | | 1 | PHOENIX 1 | | 766 | | | 53% | | 0 |
| 4 | 45 mg | 90 mg | | 12 | | | | | | |
| | | 0 | 4 | | | 12 | | 16 | | |
| | | 45 mg | 90 mg | | 12 | | 1 | | | |
| | | 28 | 40 | | | | | | | PASI |
| 75 | PASI | | 75% | | | | | | 12 | 1 |
| | | | | 40 | | | | | | |
| | | 40 | PASI | | | | | 50% | | |
| | | | | | | | | | | 76 |
| | | 2 | PHOENIX 2 | | 1,230 | | | 61% | | 0 |
| 4 | 45 mg | 90 mg | | 16 | | | | | | |
| | | 0 | 4 | | | 12 | | 16 | | |
| | | 45 mg | 90 mg | | | | | | | 52 |
| | | | | | | | | | | |
| | | 3 | ACCEPT | | 903 | | | | | |
| | | | | 12 | | | | | | |
| 2 | 50 mg | | 0 | 4 | | | | 45 mg | 90 mg | |
| | | 1 | 2 | | | | | | | PASI |
| | | 17-18 | | | BSA | | | 20 | | |
| | DLQI | | 10-12 | 1/3 | | 1 | | 1/4 | | 2 |

| | | | | | |
|-----------------------|---------|------------------------|------------------------|-----------|-----------|
| PGA ^b % | 18 (4%) | 277 (68%) ^a | 300 (73%) ^a | 241 (61%) | 279 (70%) |
| 100 kg | 290 | 297 | 289 | 287 | 280 |
| PASI 75 % | 12 (4%) | 218 (73%) | 225 (78%) | 217 (76%) | 226 (81%) |
| 100 kg | 120 | 112 | 121 | 110 | 119 |
| PASI 75 % | 3 (3%) | 55 (49%) | 86 (71%) | 59 (54%) | 88 (74%) |

^a 45 mg 90 mg p 0.001

^b PGA=

4 3 ACCEPT 12

| | 3 | | |
|--------------|-----------------|------------------------|------------------------|
| | 24 2 50mg | 2 | 0 4 |
| | | 45 mg | 90 mg |
| | 347 | 209 | 347 |
| PASI 50 % | 286 (82%) | 181 (87%) | 320 (92%) ^a |
| PASI 75 % | 197 (57%) | 141 (67%) ^b | 256 (74%) ^a |
| PASI 90 % | 80 (23%) | 76 (36%) ^a | 155 (45%) ^a |
| PGA % | 170 (49%) | 136 (65%) ^a | 245 (71%) ^a |
| 100 kg | 251 | 151 | 244 |
| PASI 75 % | 154 (61%) | 109 (72%) | 189 (77%) |
| 100 kg | 96 | 58 | 103 |
| PASI 75 % | 43 (45%) | 32 (55%) | 67 (65%) |

a

45 mg 90 mg

p 0.001

b

45 mg

p=0.012

1 PASI 75

p 0.001 1 52

PASI 75 89%

63% p 0.001 18

76 PASI 75 84%

19% 3 148

PASI 75 82% 5 244

PASI 75 80%

PASI 50%

85% 12 PASI 75

1 2 12 DLQI

28

2 4 12 24

1

SF-36 VAS

2

HADS WLQ

CDAI 220 450

8

UNITI-1 UNITI-2 44 IM-

UNITI 52

1409 UNITI-1 n=769 UNITI-2 n=640

6 CDAI 100

8

75%

0

6 mg/kg 1 130 mg

UNITI-1 TNF 48%

1 TNF 52% 2 3 TNF 69.4%

29.1% 36.4% TNF

UNITI-2 TNF 68.6% TNF

31.4%

UNITI-1 UNITI-2

5 3

8

130 mg

5 UNITI-1 UNITI-2

| | | UNITI-1* | | UNITI-2** | |
|----|-----|------------|--------------------------|------------|--------------------------|
| | | N=247 | N=249 | N=209 | N=209 |
| | 8 | 18 (7.3%) | 52 (20.9%) ^a | 41 (19.6%) | 84 (40.2%) ^a |
| 6 | 100 | 53 (21.5%) | 84 (33.7%) ^b | 60 (28.7%) | 116 (55.5%) ^a |
| 8 | 100 | 50 (20.2%) | 94 (37.8%) ^a | 67 (32.1%) | 121 (57.9%) ^a |
| 70 | 3 | 67 (27.1%) | 101 (40.6%) ^b | 66 (31.6%) | 106 (50.7%) ^a |

| | | | | | |
|----|---|------------|--------------------------|------------|--------------------------|
| 70 | 6 | 75 (30.4%) | 109 (43.8%) ^b | 81 (38.8%) | 135 (64.6%) ^a |
|----|---|------------|--------------------------|------------|--------------------------|

CDAI 150 CDAI

100

70 CDAI 70

* TNF

**

^a p 0.001

^b p 0.01

IM-UNITI UNITI-1 UNITI-2

8 100 388
90 mg 8 90 mg 12

44

44

6

6 IM-UNITI 44 52

| | | | |
|----------------------|------------------------------------|---------------------------------------|-------------------------------------|
| | [*] N=131 [†] | 90 mg 8 1 N=128 [†] | 90 mg 12 1 N=129 [†] |
| | 36% | 53% ^a | 49% ^b |
| | 44% | 59% ^b | 58% ^b |
| | 30% | 47% ^a | 43% ^c |
| | | | |
| | 46% (36/79) | 67% (52/78) ^a | 56% (44/78) |
| CRD3002 [‡] | 44% (31/70) | 63% (45/72) ^c | 57% (41/72) |

| | | | | |
|---------|--------------|-------------|--------------------------|-------------|
| TNF | | 49% (25/51) | 65% (34/52) ^c | 57% (30/53) |
| CRD3001 | ^s | 26% (16/61) | 41% (23/56) | 39% (22/57) |

CDAI 150 CDAI
 100
 *
 † 100
 ‡ TNF
 § TNF /
^a p 0.01
^b p 0.05
^c p 0.05
 IM-UNITI 29/129 12 1
 8 1
 CDAI 220 CDAI 100
 41.4% 16
 UNITI-1 UNITI-2 8
 476 IM-UNITI
 90 mg 8 50.5%
 8 44
 68.1% 50.2%
 131 51 90 mg
 8 1
 24 51 70.6%
 16 39.2%
 IM-UNITI 44
 TNF

252

5

252

SES-CD

5

/

/

8

n=155

= -2.8

SES-CD

n=97

= -0.7

p=0.012

8.8% n=26

12/15

80%

44

50%

45.5% 5/11

IBDQ

SF-36

8

UNITI-1

UNITI-2

IBDQ

SF-

36

UNITI-2

SF-36

44

IM-UNITI

252

IgG1

IL-12

IL-23

p40

IL-12

IL-23

CD⁴⁺T

IL-12R 1

| IL-12 | IL-23 | IL-12 | | | |
|---------------|-----------|-------|-------|----------|-----------|
| 26 | 1 | 10 | | 26 | |
| 45mg/kg | | | | | |
| 8.5 | | 90 mg | 45 mg | 90 mg | |
| | | | | | T_{max} |
| | | | | | T_{max} |
| | | | | | 57.2% |
| | | | | V_z | 57~83 |
| | | | | | |
| | | | | | CL |
| 1.99~2.34 ml/ | /kg | | | | |
| $t_{1/2}$ | 3 | 15~32 | | | |
| | CL/F | | V/F | 0.465 L/ | 15.7 L |
| | $t_{1/2}$ | 3 | CL/F | | |

0.09 mg/kg~4.5 mg/kg

24 mg~240 mg

C_{max}

AUC

-

0 4 12

28

0.21~0.26 μg/ml 45 mg 0.47~0.49 μg/ml 90 mg 12

126.1 μg/ml 8 90mg 8

12 1 2

90mg 8 1 12 1

1.97 μg/ml 2.24 μg/ml 0.61 μg/ml 0.76 μg/ml 90mg 12 1

90mg 8 1

100 kg 100 kg CL/F

100 kg 55% 100 kg V/F 100

kg 37% 90 mg 100 kg

45 mg 100 kg

65

CL/F V/F

12-17

CYP450

| | | | | | | | |
|--------|-----|----------|------|-------|-------|-------|--------|
| | | | | | IL-12 | IL-23 | CYP450 |
| | | 10 ng/ml | | IL-12 | / | IL-23 | CYP450 |
| CYP1A2 | 2B6 | 2C9 | 2C19 | 2D6 | 3A4 | | |

2~8

1ml I
1
1 /
36
JS20210031

45mg/0.5ml/ S20170047

90mg/1.0ml/ S20170046

Janssen-Cilag International NV
Turnhoutseweg 30, B-2340 Beerse, Belgium

Cilag AG

Hochstrasse 201, 8200 Schaffhausen, Switzerland

19


710304

400 888 9988

(029)82576616

<http://www.xian-janssen.com.cn>

1



1

1.

1 *

45 mg/0.5 ml/

- 45 mg 45 mg
- 90 mg 45 mg


90 mg/1.0 ml/

- 90 mg 90 mg

2.

2


5 cm



2

3.


3



3


4.

4




4

5




5

6



6

7




7

5.

10

6.

8



8